TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07589608: A Phase 2b, Parallel-Group, Double-Blind, Placebo-Controlled Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight and Without

Sponsor: Eli Lilly and Company · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 400 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$6,905,600

Rescue Site Savings

+$4,548,400

Unlock Full NCT07589608 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07589608 Rescue Dossier →